ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2022

The Company records share-based compensation expense on a straight-line basis over the related vesting period and recognizes forfeitures as they occur. The following table sets forth share-based compensation expense included in selling, general and administrative expense in the condensed consolidated statements of operations:


Three Months Ended March 31,
(in thousands)
2022						2021
$899						$320

Schedule of Stock Option Activity

Stock option activity under all of the Company’s Plans during the three months ended March 31, 2022 is summarized below:


	Stock Options	Weighted-average Exercise price per share		Weighted-average Remaining Contractual Life (in years)	Intrinsic Value(1) (in thousands)
Outstanding at December 31, 2021	1,350,473	$	10.10
Granted	—	—
Exercised	(1,000)	$	2.60
Forfeited or expired	(24,933)	$	37.68
Outstanding at March 31, 2022	1,324,540	$	9.59	6.25	$	7,499


(1)			Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Schedule of Restricted Stock Awards Activity

Restricted Stock Activity

Restricted stock award ("RSA") activity for the three months ended March 31, 2022 is summarized below:


	Restricted Stock Award	Weighted - Average Grant Date Fair Value
Outstanding at December 31, 2021	380,105	$	10.41
Granted	39,916	$	8.63
Vested	(10,089)	$	9.77
Forfeited or expired	(10,000)	$	20.45
Outstanding at March 31, 2022	399,932	$	9.79

Schedule of Common Stock Warrant Activity

Common stock warrant activity for the three months ended March 31, 2022 is as follows:


	Warrant Shares	Weighted-average Exercise price per share		Intrinsic Value(1) (in thousands)
Outstanding at December 31, 2021	668,907	$	2.97
Exercised	(14,728)	$	2.20
Outstanding at March 31, 2022	654,179	$	2.98	$	5,071


(1)			Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the warrant exercise price of in-the-money warrants.